Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th

Eton Pharmaceuticals (Nasdaq: ETON) announced its executive leadership will hold one-on-one meetings at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026 in Miami, Florida.

Rhea-AI Summary

Eton Pharmaceuticals (Nasdaq: ETON) announced its executive leadership will hold one-on-one meetings at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026 in Miami, Florida. Investors and institutional representatives can schedule 1x1 meetings through their Leerink Partners institutional sales representative.

Argus Feb 20 session

-1.59% close to close Open Argus

Details

News Market Reaction – ETON

On Feb 20, the day this news came out, ETON closed 1.59% below the previous close.

Data tracked by StockTitan Argus for the Feb 20 session.

Market Context

This announcement highlights ETON’s continued engagement with institutional investors through one-on...

Analysis

This announcement highlights ETON’s continued engagement with institutional investors through one-on-one meetings at a major healthcare conference on March 11, 2026. In recent months, the company combined conference participation with licensing activity and strong Q3 2025 financial growth. Investors may watch how this outreach supports interest in its rare disease portfolio, upcoming regulatory milestones, and future earnings reports, given the stock’s position below its 52-week high yet above prior lows.

Key Figures

Share price: $18.22 1-day move: 5.87% Today’s volume: 254,932 shares +5 more

Share price

$18.22

Pre-news current price for ETON

1-day move

5.87%

Price change over prior 24 hours

Today’s volume

254,932 shares

Compared with 20-day average of 225,221

52-week range

$11.0867 – $23.00

Low–high range before this news

200-day MA

$16.80

Long-term moving average level

Q3 2025 product sales

$22.5M

Reported in Q3 2025 earnings release

Q3 2025 cash

$37.1M

Cash balance at end of Q3 2025

Q3 2025 Adjusted EBITDA

$2.9M

From Q3 2025 earnings release

Historical Context

5 past events · Latest: Feb 02

5 events

1. Feb 02

   Product licensing

   24h Move

   +1.1%

   Licensed U.S. rights to ultra-rare disease product under FDA review.

2. Nov 24

   Conference appearance

   24h Move

   +2.7%

   Announced fireside chat at Piper Sandler healthcare conference.

3. Nov 12

   Conference meetings

   24h Move

   -3.3%

   Planned 1x1 meetings at Craig-Hallum Alpha Select Conference.

4. Nov 06

   Earnings release

   24h Move

   -0.6%

   Reported strong Q3 2025 sales growth and pipeline milestones.

5. Oct 23

   Earnings preview

   24h Move

   -0.4%

   Scheduled Q3 2025 results call and webcast details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DEER PARK, Ill., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will host one-on-one meetings at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026 in Miami, Florida.

To schedule a 1x1 meeting with the Company, please contact your Leerink Partners institutional sales representative.

About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eight commercial rare disease products: KHINDIVI™, INCRELEX^®, ALKINDI SPRINKLE^®, GALZIN^®, PKU GOLIKE^®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: Amglidia^®, ET-700, ET-800 and ZENEO^® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.

Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

Source: Eton Pharmaceuticals.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Eton Pharmaceuticals (ETON) meet investors at the Leerink Partners Global Healthcare Conference?

Eton will hold one-on-one meetings on Wednesday, March 11, 2026 in Miami. According to Eton, executive leadership will host 1x1 investor meetings at the Leerink Partners Global Healthcare Conference and meetings must be scheduled via Leerink institutional sales representatives.

How can investors schedule a 1x1 meeting with Eton Pharmaceuticals (ETON) for March 11, 2026?

Investors should contact their Leerink Partners institutional sales representative to schedule a meeting. According to Eton, all one-on-one meeting arrangements are handled through Leerink Partners' institutional sales team rather than directly through the company.

Who from Eton Pharmaceuticals (ETON) will attend the March 11, 2026 Leerink conference?

Members of Eton's executive leadership team will host the one-on-one meetings. According to Eton, executive leadership will represent the company in individual investor meetings at the Leerink Partners Global Healthcare Conference in Miami.

Where and what is the purpose of Eton Pharmaceuticals' (ETON) participation on March 11, 2026?

Eton will participate in one-on-one investor meetings at the Leerink Partners Global Healthcare Conference in Miami. According to Eton, the meetings provide institutional investors opportunities to discuss the company's strategy and developments with executive leadership.